Abdenour Nabid, MD, from the Centre Hospitalier de Universitaire de Sherbrooke in Sherbrooke, Canada, discusses results of a phase III randomized study that compared 18 months of ADT to 36 in men with high-risk, localized prostate cancer.
Abdenour Nabid, MD
Advertisement
Articles by Abdenour Nabid, MD
Advertisement
Latest Updated Articles
Dr. Nabid on a Shorter Duration of ADT in Prostate CancerFebruary 14th 2013
Advertisement
Advertisement
Trending on OncLive
1
Ziftomenib Plus 7+3 Elicits Durable Responses in Newly Diagnosed NPM1-Mutant and KMT2A-Rearranged AML
2
AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post–Type I JAK Inhibitor Myelofibrosis
3
Gilteritinib Yields Comparable Efficacy vs Midostaurin in Newly Diagnosed FLT3-Mutated AML but Fails to Meet Phase 3 Primary End Point
4
Fixed-Duration Pirtobrutinib/Venetoclax/Rituximab Drives PFS Benefit in R/R CLL
5